– Potential one-time therapy for the treatment of FSHD includes a novel non-cutting dCas protein delivered via a single AAV – – EPI-321 is the only therapy designed to target the epigenetic root cause of the disease – – Company on track for clinical initiation in first half of 2024 – SOUTH SAN FRANCISCO, Calif. … Read more
SOUTH SAN FRANCISCO, Calif. — November 7, 2023 — Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced that the management will participate in an upcoming investor conference: Stifel Healthcare ConferenceCorporate presentation: Wednesday, November 15 at 10:20 a.m. ET Institutional investors interested in meeting with management … Read more
– Kite will gain access to Epic Bio’s gene regulation platform to potentially develop next-generation cancer cell therapies – SANTA MONICA & SOUTH SAN FRANCISCO, Calif. — October 31, 2023 — Kite, a Gilead Company (Nasdaq: GILD)and Epicrispr Biotechnologies (“Epic Bio”), today announced the companies have entered into a research collaboration and license agreement using Epic … Read more